cover image for the 2025 Spring Prime Therapeutics Report Autoimmune management: Updates and challenges Prime Therapeutics /spring-2025-prime-therapeutics-report The Prime Therapeutics Report is...

Forbes: Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

BioSpace: While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment